VIENNA, July 14 --

Elan Corporation, plc (NYSE: ELN) and Wyeth (NYSE: WYE) presented information
this week at the Alzheimer Association 2009 International Conference on
Alzheimer’s Disease (ICAD 2009) from seven posters and one podium
presentation about the growing burden of care and costs associated with
Alzheimer’s disease (AD) and how to measure them. This information sheds
light on the impact of AD, which, as the population ages, will place a
significant and increasing burden on patients, families, and caregivers, as well
as public health systems worldwide. The costs of Alzheimer’s disease are
difficult to estimate, highlighting the importance of the information presented.

These analyses provide important information - in some cases for the first time
- about the associations between AD and the health and wellbeing of patients,
healthcare costs, and the burden on caregivers, said study investigator, Daniel
Murman, M.D., M.S., Associate Professor and Director, Memory Disorders and
Behavior Neurology Program with the Department of Neurological Sciences at the
University of Nebraska Medical Center. This information shows that not only are
AD patients more likely than their peers to suffer from other serious
conditions, but their needed care takes a tremendous toll on their caregivers.
All of this means increased burden and financial costs to individuals and the
healthcare system.

About the Poster Presentations

Poster #P3-221: Predicting Costs of Care for Unique Dependence Levels in
Patients with AD (Murman DL, et al.)

A new, longitudinal, non-interventional study of 133 Alzheimer’s disease
patients/caregiver pairs showed an exponential relationship between total costs
and AD dependence levels, with costs increasing significantly with increasing
dependence. In this study, dependence level provided a useful method to estimate
unique levels of care and associated costs that can be used in pharmacoeconomic
evaluations of new treatments for AD patients in a transparent and meaningful

Poster #P1-180: Relationship Between Patient Dependence and Caregiver Burden in
Alzheimer’s Disease (Lacey LA, et al.)

A new, longitudinal, non-interventional study that included 155
Alzheimer’s disease patients/caregiver pairs across the U.S. and Europe
assessed the relationship of AD patients’ dependence on caregiver burden,
connecting the impact of worsening AD severity on family members or other
caregivers. This is the first study exploring the relationship between
dependence and caregiver-reported burden via the Caregiver Reaction Assessment,
a tool that captures both negative and positive reactions of giving care in an
informal setting. Specifically, this poster presented an interim analysis that
found caregivers reported experiencing increased disruption in daily schedules,
greater lack of family support, and more time devoted to being a caregiver as AD
patients’ dependence increased.

Given these recent findings, it’s vital for continued research,
measurement, and documentation of the growing burden of care and cost of
Alzheimer’s disease to adequately provide support for caregivers and
assess patient healthcare needs, said Dr. Dale P. Schenk, Executive Vice
President and Chief Scientific Officer of Elan. Elan and Wyeth, through the
Alzheimer’s Immunotherapy Program (AIP), are committed to advancing
research in all aspects of the disease.

Poster #P2-071: Increased Risk of Serious Comorbidities in a Cohort of AD
Patients Compared to a Similar Non-AD Cohort (Malone D, et al.)

A retrospective data analysis showed that AD patients appear to have a higher
prevalence of certain serious conditions compared to patients without AD. These
analyses were comprised of an evaluation of claims data for more than 33 million
Americans from a managed care population over the course of eight years. The
study authors concluded that the most notable serious conditions were decubitus
ulcers (bed sores, 5-fold higher), seizures (4-fold higher), hip fractures,
(3-fold higher), depression (3-fold higher), and pneumonia (2-fold higher).

According to Professor Roy Jones, Director, The Research Institute for the Care
of Older People, Bath, United Kingdom, these conditions alone can add
significant burden to patients and their loved ones, but in combination with AD,
they often translate into significant financial cost, poor health outcomes, and
higher risk of death. I regularly see elderly patients who have multiple
conditions that increase the complexity of their care, but until now there have
been little data available to reflect the significance and increased prevalence
of other conditions in people with Alzheimer’s disease, Professor Jones

Poster #P2-066: Web-Based Application to Estimate and Project the Burden of
Alzheimer’s Disease and Evaluate the Impact of Potential Interventions
(Colantuoni E, et al.)

More than 26 million people worldwide are estimated to have Alzheimer’s
disease; however, an updated model suggests that global AD prevalence can be
expected to increase to over 100 million by 2050. The Web-based application
presented in the poster allowed cost estimate calculations on the future burden
of AD. The tool was shown to generate projections for a specified population and
generate estimates of disease burden, costs, and/or Disability Adjusted Life
Years (DALYs), along with the impact of interventions that can reduce risk or
slow progression. Projecting the future burden of AD is important for
researchers and policy makers who are evaluating the potential impact of
interventions that may reduce disease risk or slow disease progression.

This kind of work is important and we applaud the Alzheimer’s
Immunotherapy Program (AIP) for supporting research to better understand the
burden of this disease and its impact on affected families, said Marc Wortman,
Executive Director, Alzheimer’s Disease International.

Editors Note: The following Elan and Wyeth abstracts were also presented at

-- Poster #P1-204: Estimating HRQOL for Unique Dependence Levels in Patients
with AD (Murman DL, et al.) -- Poster #P3-113: Hip Fracture Risk and Subsequent
Mortality among Alzheimer’s Disease Patients in the United Kingdom,
1988-2007 (Baker NL, et al.) -- Poster #P1-212: Estimating Dependence Scale
Scores Based on Clinical Dementia Rating-Sum of Boxes Scores in Patients with
Mild Cognitive Impairment or Mild to Moderate Alzheimer’s Disease (Cohen
J, et al.) -- Podium: Development of an Algorithm for Identifying AD Severity in
Administrative Claims Data (Mucha L, et al.)

About Alzheimer’s Disease

It is estimated that one in eight baby boomers will develop AD, resulting in
significant costs to society and individuals. Recent data estimate the cost of
dementia including AD at nearly US$120 billion annually in direct and indirect
costs in Europe and US$148 billion in the U.S.

Alzheimer’s disease is a progressive brain disorder that gradually
destroys a person’s memory and ability to learn, reason, make judgments,
communicate and carry out daily activities, such as bathing and eating. As
Alzheimer’s disease progresses, individuals may also experience changes in
personality and behavior, such as anxiety, suspiciousness or agitation, as well
as delusions or hallucinations.

About the Elan and Wyeth Collaboration

The Alzheimer’s Immunotherapy Program (AIP) is a collaboration between
Elan and Wyeth to research, develop, and commercialize immunotherapeutic
approaches that may be used to treat and possibly prevent the onset of
Alzheimer’s disease. The AIP is committed to researching the burden of
care and cost of AD as well as developing tools that help advance these efforts.
The AIP is also currently conducting clinical trial enrollment throughout Europe
and the United States for its lead investigative compound bapineuzumab.

An extensive global Phase 3 clinical program was initiated in December 2007 for
bapineuzumab as a potential treatment for patients with mild to moderate
Alzheimer’s disease. To learn more about this trial and potential
enrollment, patients or caregivers should contact clinical sites directly.
Participating clinical sites in North America can be found by visiting or calling 1-888-818-MEMORY. For study information outside
North America, visit Study site details also can be
found on In addition, the AIP is continuing to conduct
safety trials with bapineuzumab subcutaneous and ACC-001.

About Elan

Elan Corporation, plc is a neuroscience-based biotechnology company committed
to making a difference in the lives of patients and their families by dedicating
itself to bringing innovations in science to fill significant unmet medical
needs that continue to exist around the world. Elan shares trade on the New
York, London and Dublin Stock Exchanges. For additional information about the
company, please visit

About Wyeth

Wyeth (NYSE:WYE) is one of the world’s largest research-driven
pharmaceutical and health care products companies. It is a leader in the
discovery, development, manufacturing and marketing of pharmaceuticals,
vaccines, biotechnology products, nutritionals and non-prescription medicines
that improve the quality of life for people worldwide. The Company’s major
divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort
Dodge Animal Health.

Safe Harbor/Forward-Looking Statements

The statements in this press release regarding the Alzheimer’s
Immunotherapy Program, including the clinical program for bapineuzumab, are
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or implied
by such statements. In particular, there can be no assurance that the clinical
program for bapineuzumab will be successful in demonstrating safety and/or
efficacy, that we will not encounter problems or delays in clinical development,
or that bapineuzumab will ever receive regulatory approval or be successfully
commercialized. Other risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by these forward-looking
statements include those detailed from time to time in the companies’
periodic reports filed with the Securities and Exchange Commission, including
Wyeth`s current reports on Form 8-K, quarterly reports on Form 10-Q and annual
report on Form 10-K, particularly the discussion under the caption Item 1A, Risk
Factors in Wyeth’s Annual Report on Form 10-K for the year ended December
31, 2008, which was filed with the Securities and Exchange Commission on
February 27, 2009, and Elan’s Reports of Foreign Issuer on Form 6-K and
Annual Report on Form 20-F, particularly the discussion under the caption Item
3D, Risk Factors in Elan’s Annual Report on Form 20-F for the year ended
December 31, 2008, which was filed with the Securities and Exchange Commission
on February 26, 2009 The forward-looking statements in this press release are
qualified by these risk factors. The companies assume no obligation to publicly
update any forward-looking statements, whether as a result of new information,
future developments or otherwise.

SOURCE: Wyeth Pharmaceuticals

investors, Chris Burns, +1-800-252-3526, or David Marshall, +353-1-709-4444,
both of Elan, or Justin Victoria, +1-973-660-5340 of Wyeth; media, Mary Stutts,
+1-650-794-4403 or +1-650-823-5255, or Miriam Mason, +1-650-238-7113 or
+1-650-877-7616, both of Elan, or Douglas Petkus, +1-973-660-5218, or Gwendolyn
Fisher, +1-484-865-5160, both of Wyeth